Project Grant R43AI152717

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,969 Project Grant to L2 Diagnostics LLC under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to evaluate a mosquito salivary protein, AGBR1, as a potential vaccine candidate against Chikungunya virus, an arboviral disease transmitted by infected mosquitoes. The project aims to conduct comparative assessments of different AGBR1 vaccine formulations, including...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop broadly inhibitory antibody therapies against alphaviruses such as chikungunya virus (CHIKV) and Mayaro virus (MAYV). The $843,620 award to Albert Einstein College of Medicine, a private non-profit research institution, will fund efforts to: 1) engineer Fc mutations into existing broadly protective antibodies to...

The Flavivirus and Alphavirus REVAMPP (FLARE) Center, funded by a $46,715,173 Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), is developing and optimizing protein nanoparticle, virion-based, and mRNA vaccine platforms, as well as monoclonal antibody-based treatments to rapidly respond to emerging flaviviruses and alphaviruses with pandemic potential. The Center integrates the work of multiple...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a novel T cell-based vaccine to prevent infection from dengue virus (DENV) and Zika virus (ZIKV). The $781,718 award to Loyola University of Chicago's Health Sciences Campus aims to create a vaccine targeting the non-structural protein 3 (NS3) of ZIKV and DENV1-4, using ubiquitination and...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $760,318 to the University of California, Davis to develop and optimize recombinant enhanced antiviral sensors (REAVRs) that broadly inhibit virus replication. The REAVRs combine virus-sensing domains with effector domains from different antiviral proteins, aiming to create broadly-acting antiviral proteins. The...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $813,160 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to develop mRNA-LNP vaccines targeting multiple stages and species of the human malaria parasite. The primary focus is on vaccines targeting infection by sporozoites and mosquito transmission by gametocytes of Plasmodium falciparum and P. vivax. Key vaccine candidates include PfCSP, PFS25, and PFS230 for P. falciparum, and...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $769,737 to Yale University to develop capsid-engineered adeno-associated viral (AAV) vectors that can specifically target and deliver gene therapies to human T cells and myeloid cells. The goal is to use these AAV vectors to deliver a designer recombinase called BREC1, which can eliminate HIV provirus integrated in...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $561,538 to develop neutralizing antibodies against Machupo virus, a New World arenavirus. The project aims to utilize advanced immunization techniques, an innovative stabilized antigen, and high-throughput screening to identify and characterize antibodies that target multiple epitopes of the Machupo virus surface...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $2,178,000.00 to develop a "tunable nanophage platform" for rapid design, screening, and formulation of potential vaccine candidates against emerging infectious disease threats, including SARS-CoV-2 variants and pre-emergent SARS-like coronaviruses. Key objectives include engineering "second...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded Orlance, Inc., a woman-owned small business, a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop an enhanced seasonal influenza DNA vaccine. The project aims to combine the advantages of a closely matched seasonal influenza vaccine with a universal influenza vaccine to provide more robust and durable protection, especially for the elderly and immunocompromised...